Latest Medical Guidelines for Active TB Treatment
The 2025 ATS/CDC/ERS/IDSA guidelines now recommend shorter, all-oral regimens for active tuberculosis: a 4-month regimen for adults with drug-susceptible pulmonary TB, and 6-month all-oral regimens for drug-resistant TB using novel agents like bedaquiline, pretomanid, and linezolid. 1
Drug-Susceptible Pulmonary TB in Adults
For adults with drug-susceptible pulmonary TB, the treatment landscape has fundamentally shifted from the decades-old 6-month standard:
- 4-month regimen: This novel shortened regimen is now recommended for eligible adults with pulmonary TB 1
- The traditional 6-month regimen (2HRZE/4HR) remains an option but is no longer the sole standard
- Standard dosing includes isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) during the intensive phase
Key implementation point: Medications should be administered 7 days per week with directly observed therapy (DOT) at least 5 of 7 days per week 1
Critical Caveat
Always add pyridoxine (vitamin B6) 25-50 mg daily with isoniazid to prevent peripheral neuropathy 1. This is non-negotiable and frequently overlooked.
Drug-Resistant TB: Revolutionary Changes
The guidelines represent a paradigm shift for drug-resistant TB, moving away from prolonged injectable-containing regimens to shorter all-oral options:
Rifampin-Resistant, Fluoroquinolone-Susceptible TB
Use the 6-month BPaLM regimen (strong recommendation) in adolescents ≥14 years and adults 1:
- Bedaquiline: 400 mg daily × 2 weeks, then 200 mg three times weekly × 24 weeks
- Pretomanid: 200 mg daily × 26 weeks
- Linezolid: 600 mg daily × 26 weeks
- Moxifloxacin: 400 mg daily × 26 weeks
This replaces the previous 15+ month regimens and dramatically improves quality of life while maintaining efficacy.
Rifampin-Resistant with Fluoroquinolone Resistance/Intolerance
Use the 6-month BPaL regimen (without moxifloxacin) for patients with no prior exposure or <1 month exposure to bedaquiline and linezolid 1:
- Bedaquiline: Same dosing as above
- Pretomanid: 200 mg daily × 26 weeks
- Linezolid: 600 mg daily × 26 weeks
Administration Requirements for Drug-Resistant Regimens
- Give all medications 7 days per week with food
- Avoid milk, antacids, or other cationic items when administering these drugs 1
- Maintain DOT 5 of 7 days per week
- These are strong recommendations despite very low certainty of evidence, reflecting the urgent need for better tolerated regimens
Pediatric Considerations
For children and adolescents aged 3 months to 16 years with nonsevere drug-susceptible TB:
Use the 4-month regimen (2HRZ(E)/2HR) instead of the traditional 6-month regimen (strong recommendation, moderate certainty of evidence) 1
This applies only to nonsevere disease without suspicion of MDR/RR-TB.
Evidence Quality and Clinical Context
The 2025 ATS/CDC/ERS/IDSA guideline 1 represents the highest quality evidence available, issued by the most authoritative bodies in TB management. While some recommendations carry "very low certainty of evidence" (particularly for drug-resistant TB regimens), the strong recommendations reflect:
- The substantial improvement in treatment duration and tolerability
- The elimination of injectable agents
- Real-world implementation success
- The unacceptable burden of previous 18+ month regimens
The drug development pipeline continues to advance with DprE1 inhibitors, next-generation oxazolidinones, and other novel compounds in late-stage trials 2, suggesting further improvements are forthcoming.
Common Pitfalls to Avoid
- Do not use shortened regimens for severe TB (extensive disease, cavitation, HIV coinfection with low CD4 counts) without careful consideration
- Do not forget pyridoxine with isoniazid-containing regimens
- Do not administer BPaL/BPaLM regimens with milk or antacids - this significantly affects absorption
- Do not use BPaL/BPaLM in patients with prior significant exposure to bedaquiline or linezolid (>1 month)
- Monitor QTc intervals with bedaquiline and moxifloxacin combinations, though this has been manageable in practice 3